Literature DB >> 10781653

Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population.

Y Yamada1, H Yoshida, S Ichihara, T Imaizumi, K Satoh, M Yokota.   

Abstract

Platelet-activating factor acetylhydrolase (PAF-AH), a plasma enzyme that hydrolyzes PAF and oxidized phospholipids, is thought to be involved in protecting cells against oxidative stress. A G(994) (M allele)-->T (m allele) mutation in the plasma PAF-AH gene, which results in a Val(279)-->Phe substitution in the mature protein, leads to a loss of catalytic activity. To elucidate the relationships among PAF-AH enzyme activity, genotype, age, and atherosclerosis, we assayed these parameters in a large Japanese population (n=3932) that consisted of three groups; a control group (healthy individuals; n=1684), a risk-factor group (individuals having at least one conventional risk factor for atherosclerosis; n=1398), and a diseased group (patients who had suffered a myocardial infarction or stroke; n=850). We observed a significantly increased frequency of the m allele in the diseased group as compared with the control or risk-factor groups. Plasma PAF-AH activity increased significantly with age in women in the control group with the MM and Mm genotypes, and in men in the control group with the MM genotype, but not in men with the Mm genotype. In both the risk-factor and diseased groups, however, no correlation was observed between plasma PAF-AH activity and age in subjects with either genotype. These results suggest that in individuals with the MM genotype, plasma PAF-AH activity may be increased in response to stresses induced by PAF and/or oxidized phospholipids that might accumulate with age, but that this response is not evident or reduced in healthy individuals with the m allele, or in subjects with atherosclerotic disease, or having risk factors. Together with our previous findings, the G(994)-->T mutation in the PAF-AH gene may be one of the genetic determinants for atherosclerotic disease in the Japanese population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781653     DOI: 10.1016/s0021-9150(99)00385-8

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  27 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Effects of A379V variant of the Lp-PLA 2 gene on Lp-PLA 2 activity and markers of oxidative stress and endothelial function in Koreans.

Authors:  Jey Sook Chae; Jung Hyun Kwak; Minjoo Kim; Kyoung Hun Shin; Sang-Hyun Lee; Tae-Sook Jeong; Jong Ho Lee
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300

3.  Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.

Authors:  Parveen K Garg; Robyn L McClelland; Nancy S Jenny; Michael H Criqui; Philip Greenland; Robert S Rosenson; David S Siscovick; Neal Jorgensen; Mary Cushman
Journal:  Atherosclerosis       Date:  2015-05-16       Impact factor: 5.162

4.  Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Thomas A Pearson; Lars Berglund
Journal:  Atherosclerosis       Date:  2010-04-20       Impact factor: 5.162

Review 5.  Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

Authors:  Giuseppe Maiolino; Valeria Bisogni; Giacomo Rossitto; Gian Paolo Rossi
Journal:  World J Cardiol       Date:  2015-10-26

6.  Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA2 Inhibitor.

Authors:  Nicholas D Measom; Kenneth D Down; David J Hirst; Craig Jamieson; Eric S Manas; Vipulkumar K Patel; Don O Somers
Journal:  ACS Med Chem Lett       Date:  2016-11-15       Impact factor: 4.345

7.  Platelet-activating factor and P-selectin activities in thrombotic and nonthrombotic Behçet's patients.

Authors:  S Ercan Tunc; Kenan Aksu; Gokhan Keser; Fahrettin Oksel; Eker Doganavsargil; Timur Pirildar; Tufan Turk; Ender Terzioglu; Afig Huseyinov
Journal:  Rheumatol Int       Date:  2004-03-05       Impact factor: 2.631

8.  Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients.

Authors:  Mitsuaki Ishihara; Tadao Iwasaki; Makoto Nagano; Jun Ishii; Mayumi Takano; Takeshi Kujiraoka; Masahiro Tsuji; Hiroaki Hattori; Mitsuru Emi
Journal:  J Hum Genet       Date:  2004-05-18       Impact factor: 3.172

9.  Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population.

Authors:  Guo-Hua Zheng; Shang-Quan Xiong; Hai-Ying Chen; Li-Juan Mei; Ting Wang
Journal:  Mol Biol Rep       Date:  2014-07-18       Impact factor: 2.316

10.  Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study.

Authors:  Emmanouil S Brilakis; Amit Khera; Darren K McGuire; Raphael See; Subhash Banerjee; Sabina A Murphy; James A de Lemos
Journal:  Atherosclerosis       Date:  2007-12-03       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.